| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Source | Endogenous metabolite |
| Molecular weight | |
| Molecular formula | C15H20N2O11 |
| Purity | |
| Activity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Nicotinamide riboside tartrate is an orally active NAD+ precursor that increases NAD+ levels and activates SIRT1 and SIRT3. It serves as a source of vitamin B3 (niacin) and enhances oxidative metabolism, offering protection against high-fat-diet-induced metabolic abnormalities[1]. It also reduces cognitive deterioration in a transgenic mouse model of Alzheimer's disease[2]. It is supplied as a white to off-white solid (C15H20N2O11, MW 404.33) at 98.07% purity.
Physical & Chemical Properties
| CAS Number | 2415657-86-0 |
|---|---|
| Molecular Formula | C15H20N2O11 |
| Molecular Weight | 404.33 g/mol |
| Purity | 98.07% |
| Appearance | Solid |
| Color | White to off-white |
| Structure Classification | Others |
| SMILES | O[C@@H](C([O-])=O)[C@@H](O)C(O)=O.NC(C1=C[N+]([C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)=CC=C1)=O |
| Target | SIRT1, SIRT3 |
| Signaling Pathway | Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease |
| Bioactivity Class | Human Endogenous Metabolite |
| Initial Source | Endogenous metabolite |
| Solubility | In Vitro: H2O: 100 mg/mL (247.32 mM; Requires sonication) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| H2O | 100 mg/mL (247.32 mM) | requires sonication |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
If water is used as the stock solvent, dilute to the working solution and sterilize it through a 0.22 μm filter before use.
Data provided by the manufacturer.
In Vitro
Nicotinamide riboside tartrate (0.5 mM; 24 hours) lowers the acetylation status of Ndufa9 and SOD2[1]. In C2C12, Hepa1.6, and HEK293 cells, Nicotinamide riboside tartrate (1-1000 μM) concentration-dependently raises intracellular and mitochondrial NAD+ content[1]. Nicotinamide riboside tartrate raises NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions that support innate immunity against coronavirus (CoVs), a cause of COVID-19[3].
Western Blot Analysis[1]
| Cell Line | HEK293T cells |
|---|---|
| Concentration | 0.5 mM |
| Incubation Time | 24 hours |
| Result | Reduced the acetylation status of Ndufa9 and SOD2. |
In Vivo
Chronic supplementation with Nicotinamide riboside tartrate (p.o.; 400 mg/kg/day; for 16 weeks) elevates plasma and intracellular NAD+ content in a tissue-specific manner[1].
| Animal Model | 10-week-old C57Bl/6J mice[1] |
|---|---|
| Dosage | 400 mg/kg |
| Administration | PO; daily; for 16 weeks |
| Result | Increased plasma and intracellular NAD+ content in a tissue-specific manner. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Vitamin B2 and B3 nutrigenomics reveals a therapy for NAXD disease. Cell 2026 Apr 30;189(9):2648-2662.e19. PMID: 41747729
Isovitexin targets SIRT3 to prevent steroid-induced osteonecrosis of the femoral head by modulating mitophagy-mediated ferroptosis. Bone Res 2025 Jan 26;13(1):18. PMID: 39865068
The metabolite alpha-ketobutyrate extends lifespan by promoting peroxisomal function in C. elegans. Nat Commun 2023 Jan 16;14(1):240. PMID: 36646719
Inhibition of mitochondrial complex I leading to NAD+/NADH imbalance in type 2 diabetic patients who developed late stent thrombosis: Evidence from an integrative analysis of platelet bioenergetics and metabolomics. Redox Biol 2022 Nov:57:102507. PMID: 36244294
Metabolically engineered probiotic OMVs as nanovaccine mediating sequential immunomodulation for chronic bone infection immunotherapy. Cell Rep Med 2026 Jun 16;7(6):102842. PMID: 42229426
Chem Eng J. 2026 Mar 5.
NAMPT is a metabolic checkpoint of IFNγ-producing CD4+ T cells in lupus nephritis. Mol Ther 2023 Jan 4;31(1):193-210. PMID: 36146932
Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside. Basic Res Cardiol 2024 Jun;119(3):403-418. PMID: 38528175
Hesperidin mitigates copper nanoparticle exposure-induced mitochondrial unfolded protein response through the SIRT3-FOXO3A signaling pathway. Int J Biol Macromol 2025 Jul 5;320(Pt 1):145750. PMID: 40617440
Engineered Stem Cell Membrane-Coated Nanodrugs for Targeted Therapy of Alzheimer's Disease. ACS Appl Mater Interfaces 2025 Aug 20;17(33):47497-47511. PMID: 40768614
